Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy
详细信息 查看全文
- 作者：Martin Chasen ; Laszlo Urban ; Ian Schnadig ; Bernardo Rapoport…
- 关键词：Rolapitant ; Neurokinin ; 1 receptor antagonist ; Quality of life ; Functional Living Index ; Emesis ; Chemotherapy ; induced nausea and vomiting (CINV) ; Antiemetic
- 刊名：Supportive Care in Cancer
- 出版年：2017
- 出版时间：January 2017
- 年：2017
- 卷：25
- 期：1
- 页码：85-92
- 全文大小：446KB
- 刊物类别：Medicine
- 刊物主题：Oncology; Nursing; Nursing Research; Pain Medicine; Rehabilitation Medicine;
- 出版者：Springer Berlin Heidelberg
- ISSN：1433-7339
- 卷排序：25
文摘
PurposeAddition of rolapitant to standard antiemetic therapy improved protection against chemotherapy-induced nausea and vomiting (CINV) in phase 3 trials of patients receiving highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC). Here, we assessed the impact of CINV on the daily lives of patients receiving HEC or MEC using the Functional Living Index-Emesis (FLIE).